Jianguo Gao1,
Jianer Tang1,
Yu Chen1,
Junwen Shen1,
Ning Wang1,
Zhihai Fang1,
Guiqin Shen1,
Fan Ren2,
Rongjiang Wang1 
For correspondence:- Rongjiang Wang Email: rongjiangwang@hotmail.com Tel:+865728465355
Accepted: 12 May 2018 Published: 30 June 2018
Citation: Gao J, Tang J, Chen Y, Shen J, Wang N, Fang Z, et al. N-(4-hydroxyphenyl) retinamide inhibits migration of renal carcinoma cells and promotes autophagy via MAPK p38 pathway. Trop J Pharm Res 2018; 17(6):1003-1009 doi: 10.4314/tjpr.v17i6.4
© 2018 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To investigate the effect of N-(4-hydroxyphenyl) retinamide (4HPR) on autophagy and migration of renal carcinoma cells.
Methods: Renal cancer cell lines were treated with various concentrations of 4HPR. Proliferation of the cells was studied using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltrazolium bromide (MTT), while apoptosis and cell cycle arrest were determined by flow cytometry.
Results: Treatment of RCCs with 30 µM 4HPR caused significant inhibition of viability. In 786-O and OS-RC-2 cell lines, 4HPR reduced colony formation by 39 and 43 %, respectively. In addition, 4HPR increased the percentage of 786-O cells in G1 phase from 58.79 ± 3.43 to 71.68 ± 4.47 % (p < 0.05). It also decreased the percentage of cells in the S-phase from 21.98 ± 2.78 to 09.17 ± 1.43 %, and enhanced the activation of p38 and JNK in 786-O cells at 48 h. Western blot assay showed that the activation of p38 and JNK by 4HPR was inhibited on pre-treatment with SB203580 (inhibitor of p38) and SP600125 (inhibitor of JNK), respectively. Reduction of 786-O cell viability by 4HPR treatment was also significantly inhibited by pre-treatment with sp203580 and sp600125 (p < 0.05). Furthermore, the inhibitors also reversed the effect of 4HPR on the ex
Conclusion: These results indicate that 4HPR inhibits the growth of renal cancer cells via activation of MAPK signalling pathway. Thus, 4HPR is a potential drug target for management of renal cancer.
Archives
News Updates
Fulltext in PDF